Clinical Trial Update: An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD) [Phase 4]

View source ↗

Summary

Phase 4 efficacy and safety study of osmotic-release methylphenidate in individuals with attention-deficit/hyperactivity disorder has completed and results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• CONCERTA (METHYLPHENIDATE HYDROCHLORIDE)

Snippet

Sponsor: Janssen Korea, Ltd., Korea | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 4 | Status: COMPLETED | Results posted: 2014-02-06